Pyxis Oncology initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Pyxis Oncology with a Buy rating and $15 price target. Pyxis – whose goal is to develop therapies against hard-to-treat cancers by building a superior portfolio of therapeutic products including antibody-dependent conjugates, or ADCs, and monoclonal antibody immunotherapies – “represents to us the ‘New, new'” and possesses two broad platforms and has acquired a third, the analyst tells investors.